Business Context and Reporting Period
This Form 8-K filing by ENDRA Life Sciences Inc. (NDRA) is dated July 8, 2026. The report addresses the company's compliance status with Nasdaq listing requirements following a previous deficiency notice regarding stockholders' equity.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only financial metric referenced is the Minimum Stockholders' Equity Requirement of $2,500,000 set forth in Nasdaq Listing Rule 5550(b)(1). The company previously reported equity below this threshold in its 2025 Annual Report (Form 10-K) but has since regained compliance.
Material Changes
- Regained Compliance: On July 8, 2026, Nasdaq issued a Notice confirming the Company has regained compliance with the Minimum Stockholders' Equity Requirement.
- Monitoring Status: The Company is now subject to a Discretionary Panel Monitor for a period of one year, effective July 1, 2026, pursuant to Nasdaq Listing Rule 5815(d)(4)(A).
Outlook, Risks, and Contingencies
The filing outlines significant risks associated with the one-year monitoring period:
- Strict Enforcement: If the Company falls out of compliance with any Nasdaq Listing Rule during the monitoring period, it will not be permitted to submit a plan of compliance or receive additional cure periods.
- Delisting Risk: In the event of a new deficiency, Nasdaq will issue a Delist Determination Letter immediately. The Company would then have the opportunity to request a hearing, but its securities may be delisted from Nasdaq.
Investor Verification Checklist
- Verify the specific financial actions taken to restore stockholders' equity above the $2,500,000 threshold.
- Monitor the company's stock price and equity levels closely to ensure no further breaches occur during the one-year discretionary monitoring period.
- Review the most recent Form 10-K (for the year ended December 31, 2025) to understand the baseline financial position that triggered the initial deficiency.